LDR vs. HDR Brachytherapy for Prostate Cancer

  • End date
    Dec 31, 2026
  • participants needed
  • sponsor
    British Columbia Cancer Agency
Updated on 26 January 2021
antiandrogen therapy
androgen suppression
transrectal ultrasound


H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103


Men suitable for prostate brachytherapy as monotherapy will undergo multiparametric Magnetic Resonance Imaging for staging and identification of a dominant lesion and will be randomly selected for either a single low dose rate permanent seed implant or 2 fractions of high dose rate brachytherapy. Using image registration techniques, dominant lesions will be biopsied under anesthesia at the start of the brachytherapy procedure. Biopsies will reviewed for tumor Gleason score and sent for Cell Cycle Progression testing (Prolaris). Patients receiving high dose rate brachytherapy will also have biopsies between the 2 fractions to assess tumor changes induced from the first fraction. Post implant quality assurance will determine the dose to the dominant lesions and compare these between the 2 types of brachytherapy. Post implant symptoms will be tracked for severity and time course.

Condition Malignant neoplasm of prostate, Prostate Cancer, Prostate Cancer, Early, Recurrent, Prostatic disorder, Prostate Disorders, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
Clinical Study IdentifierNCT03426748
SponsorBritish Columbia Cancer Agency
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Favorable risk and low-tier intermediate-risk prostate cancer with estimated
life expectancy of at least 10 years
Clinical stage T1c-T2b, PSA < 20, Gleason < 8
ECOG 0-1
Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor
Extensive favorable-risk disease is defined as
clinical stage T1c-T2a
PSA < 10
Gleason 6
% of biopsy cores containing cancer
PSA density > 0.2 ng/cc
Selected intermediate risk patients not defined above
\- T1c/T2a
\- PSA < 10
Gleason 4+3
< 33% of cores involved
Max tumor length in any core 10 mm
No androgen deprivation therapy (ADT)
Prostate volume by TRUS 60 cc
Not eligible for, or accepting of, active surveillance according to NCCN guidelines
Signed study specific informed consent

Exclusion Criteria

Prior radical surgery for carcinoma of the prostate
Prior pelvic radiation
Prior chemotherapy for prostate cancer
Prior TURP or cryosurgery of the prostate
Claustrophobic or unable to undergo MRI
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note